Global Targeted Small Molecule Therapy Market Research Report 2025

Publication ID:

PB501251697

Publication Date:

January 22, 2025

Pages:

100

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Targeted Small Molecule Therapy was valued at US$ 61670 million in the year 2024 and is projected to reach a revised size of US$ 113940 million by 2031, growing at a CAGR of 9.3% during the forecast period.
Targeted therapy is听a type of cancer treatment that uses drugs or other substances to precisely identify and attack certain types of cancer cells. A targeted therapy can be used by itself or in combination with other treatments, such as traditional or standard chemotherapy, surgery, or radiation therapy.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Targeted Small Molecule Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Small Molecule Therapy.
The Targeted Small Molecule Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Targeted Small Molecule Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Small Molecule Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Eisai
Zelgen
Cipla
Natco Pharma
AstraZeneca
Novartis
Roche
Bristol-Myers Squibb
Pfizer
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere
Segment by Type
Sorafenib
Lenvatinib
Regorafenib
Osimertinib
Anlotinib
Alectinib
Other
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Small Molecule Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Small Molecule Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Sorafenib
1.2.3 Lenvatinib
1.2.4 Regorafenib
1.2.5 Osimertinib
1.2.6 Anlotinib
1.2.7 Alectinib
1.2.8 Other
1.3 Market by Application
1.3.1 Global Targeted Small Molecule Therapy Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Small Molecule Therapy Market Perspective (2020-2031)
2.2 Global Targeted Small Molecule Therapy Growth Trends by Region
2.2.1 Global Targeted Small Molecule Therapy Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Targeted Small Molecule Therapy Historic Market Size by Region (2020-2025)
2.2.3 Targeted Small Molecule Therapy Forecasted Market Size by Region (2026-2031)
2.3 Targeted Small Molecule Therapy Market Dynamics
2.3.1 Targeted Small Molecule Therapy Industry Trends
2.3.2 Targeted Small Molecule Therapy Market Drivers
2.3.3 Targeted Small Molecule Therapy Market Challenges
2.3.4 Targeted Small Molecule Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Small Molecule Therapy Players by Revenue
3.1.1 Global Top Targeted Small Molecule Therapy Players by Revenue (2020-2025)
3.1.2 Global Targeted Small Molecule Therapy Revenue Market Share by Players (2020-2025)
3.2 Global Targeted Small Molecule Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Targeted Small Molecule Therapy Revenue
3.4 Global Targeted Small Molecule Therapy Market Concentration Ratio
3.4.1 Global Targeted Small Molecule Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Small Molecule Therapy Revenue in 2024
3.5 Global Key Players of Targeted Small Molecule Therapy Head office and Area Served
3.6 Global Key Players of Targeted Small Molecule Therapy, Product and Application
3.7 Global Key Players of Targeted Small Molecule Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Small Molecule Therapy Breakdown Data by Type
4.1 Global Targeted Small Molecule Therapy Historic Market Size by Type (2020-2025)
4.2 Global Targeted Small Molecule Therapy Forecasted Market Size by Type (2026-2031)
5 Targeted Small Molecule Therapy Breakdown Data by Application
5.1 Global Targeted Small Molecule Therapy Historic Market Size by Application (2020-2025)
5.2 Global Targeted Small Molecule Therapy Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Targeted Small Molecule Therapy Market Size (2020-2031)
6.2 North America Targeted Small Molecule Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Targeted Small Molecule Therapy Market Size by Country (2020-2025)
6.4 North America Targeted Small Molecule Therapy Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Small Molecule Therapy Market Size (2020-2031)
7.2 Europe Targeted Small Molecule Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Targeted Small Molecule Therapy Market Size by Country (2020-2025)
7.4 Europe Targeted Small Molecule Therapy Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Small Molecule Therapy Market Size (2020-2031)
8.2 Asia-Pacific Targeted Small Molecule Therapy Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Targeted Small Molecule Therapy Market Size by Region (2020-2025)
8.4 Asia-Pacific Targeted Small Molecule Therapy Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Small Molecule Therapy Market Size (2020-2031)
9.2 Latin America Targeted Small Molecule Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Targeted Small Molecule Therapy Market Size by Country (2020-2025)
9.4 Latin America Targeted Small Molecule Therapy Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Small Molecule Therapy Market Size (2020-2031)
10.2 Middle East & Africa Targeted Small Molecule Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Targeted Small Molecule Therapy Market Size by Country (2020-2025)
10.4 Middle East & Africa Targeted Small Molecule Therapy Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Targeted Small Molecule Therapy Introduction
11.1.4 Bayer Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.1.5 Bayer Recent Development
11.2 Eisai
11.2.1 Eisai Company Details
11.2.2 Eisai Business Overview
11.2.3 Eisai Targeted Small Molecule Therapy Introduction
11.2.4 Eisai Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.2.5 Eisai Recent Development
11.3 Zelgen
11.3.1 Zelgen Company Details
11.3.2 Zelgen Business Overview
11.3.3 Zelgen Targeted Small Molecule Therapy Introduction
11.3.4 Zelgen Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.3.5 Zelgen Recent Development
11.4 Cipla
11.4.1 Cipla Company Details
11.4.2 Cipla Business Overview
11.4.3 Cipla Targeted Small Molecule Therapy Introduction
11.4.4 Cipla Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.4.5 Cipla Recent Development
11.5 Natco Pharma
11.5.1 Natco Pharma Company Details
11.5.2 Natco Pharma Business Overview
11.5.3 Natco Pharma Targeted Small Molecule Therapy Introduction
11.5.4 Natco Pharma Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.5.5 Natco Pharma Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Targeted Small Molecule Therapy Introduction
11.6.4 AstraZeneca Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.6.5 AstraZeneca Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Targeted Small Molecule Therapy Introduction
11.7.4 Novartis Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 Roche
11.8.1 Roche Company Details
11.8.2 Roche Business Overview
11.8.3 Roche Targeted Small Molecule Therapy Introduction
11.8.4 Roche Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.8.5 Roche Recent Development
11.9 Bristol-Myers Squibb
11.9.1 Bristol-Myers Squibb Company Details
11.9.2 Bristol-Myers Squibb Business Overview
11.9.3 Bristol-Myers Squibb Targeted Small Molecule Therapy Introduction
11.9.4 Bristol-Myers Squibb Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.9.5 Bristol-Myers Squibb Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Details
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Targeted Small Molecule Therapy Introduction
11.10.4 Pfizer Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.10.5 Pfizer Recent Development
11.11 BEACON Pharma
11.11.1 BEACON Pharma Company Details
11.11.2 BEACON Pharma Business Overview
11.11.3 BEACON Pharma Targeted Small Molecule Therapy Introduction
11.11.4 BEACON Pharma Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.11.5 BEACON Pharma Recent Development
11.12 Jiangxi Shanxiang
11.12.1 Jiangxi Shanxiang Company Details
11.12.2 Jiangxi Shanxiang Business Overview
11.12.3 Jiangxi Shanxiang Targeted Small Molecule Therapy Introduction
11.12.4 Jiangxi Shanxiang Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.12.5 Jiangxi Shanxiang Recent Development
11.13 Yao Pharma
11.13.1 Yao Pharma Company Details
11.13.2 Yao Pharma Business Overview
11.13.3 Yao Pharma Targeted Small Molecule Therapy Introduction
11.13.4 Yao Pharma Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.13.5 Yao Pharma Recent Development
11.14 CSPC
11.14.1 CSPC Company Details
11.14.2 CSPC Business Overview
11.14.3 CSPC Targeted Small Molecule Therapy Introduction
11.14.4 CSPC Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.14.5 CSPC Recent Development
11.15 CHIATAI Tianqing
11.15.1 CHIATAI Tianqing Company Details
11.15.2 CHIATAI Tianqing Business Overview
11.15.3 CHIATAI Tianqing Targeted Small Molecule Therapy Introduction
11.15.4 CHIATAI Tianqing Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.15.5 CHIATAI Tianqing Recent Development
11.16 Simcere
11.16.1 Simcere Company Details
11.16.2 Simcere Business Overview
11.16.3 Simcere Targeted Small Molecule Therapy Introduction
11.16.4 Simcere Revenue in Targeted Small Molecule Therapy Business (2020-2025)
11.16.5 Simcere Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Bayer
Eisai
Zelgen
Cipla
Natco Pharma
AstraZeneca
Novartis
Roche
Bristol-Myers Squibb
Pfizer
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂